Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTX NASDAQ:MRVI NASDAQ:NAMS NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$58.97-1.3%$53.52$1.16▼$14.10$2.56B-0.12189,291 shs373,398 shsMRVIMaravai LifeSciences$2.22-5.1%$2.40$1.66▼$9.95$595.90M0.281.51 million shs1.18 million shsNAMSNewAmsterdam Pharma$21.28-2.4%$20.18$14.06▼$27.29$2.45B-0.03776,378 shs537,520 shsRAREUltragenyx Pharmaceutical$28.44+4.1%$33.99$25.81▼$60.37$2.58B0.253.19 million shs2.24 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics+0.69%-1.35%+16.88%+20.70%+36.38%MRVIMaravai LifeSciences-5.13%-17.47%-16.23%+7.25%-77.18%NAMSNewAmsterdam Pharma-2.43%-9.83%+12.24%+6.24%+24.30%RAREUltragenyx Pharmaceutical+4.10%+4.02%-27.93%-27.63%-36.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMRVIMaravai LifeSciences3.7465 of 5 stars3.11.00.04.42.70.81.3NAMSNewAmsterdam Pharma3.1979 of 5 stars4.41.00.00.01.55.00.0RAREUltragenyx Pharmaceutical4.4722 of 5 stars4.51.00.03.83.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/AMRVIMaravai LifeSciences 2.25Hold$6.64199.05% UpsideNAMSNewAmsterdam Pharma 2.89Moderate Buy$41.3094.08% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$83.08192.11% UpsideCurrent Analyst Ratings BreakdownLatest MRVI, NAMS, GMTX, and RARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$80.007/17/2025NAMSNewAmsterdam PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$27.007/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$35.00 ➝ $34.007/14/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.007/10/2025RAREUltragenyx PharmaceuticalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$88.00 ➝ $65.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.006/17/2025NAMSNewAmsterdam PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.006/12/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.006/10/2025NAMSNewAmsterdam PharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$44.006/4/2025NAMSNewAmsterdam PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.005/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AMRVIMaravai LifeSciences$259.18M2.18$0.59 per share3.79$2.28 per share0.97NAMSNewAmsterdam Pharma$47.14M50.68N/AN/A$8.20 per share2.60RAREUltragenyx Pharmaceutical$560.23M4.80N/AN/A$2.76 per share10.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AMRVIMaravai LifeSciences-$144.85M-$1.14N/AN/AN/A-67.14%-12.91%-6.87%8/11/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.88N/AN/AN/A-397.45%-37.34%-33.45%8/6/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%8/5/2025 (Estimated)Latest MRVI, NAMS, GMTX, and RARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025MRVIMaravai LifeSciences-$0.06N/AN/AN/A$47.46 millionN/A8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52N/AN/AN/A$1.44 millionN/A8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27N/AN/AN/A$161.37 millionN/A5/12/2025Q1 2025MRVIMaravai LifeSciences-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49MRVIMaravai LifeSciences0.605.965.17NAMSNewAmsterdam PharmaN/A19.9819.98RAREUltragenyx PharmaceuticalN/A2.402.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%MRVIMaravai LifeSciences50.25%NAMSNewAmsterdam Pharma89.89%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%MRVIMaravai LifeSciences2.11%NAMSNewAmsterdam Pharma20.84%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableMRVIMaravai LifeSciences610254.66 million249.29 millionOptionableNAMSNewAmsterdam Pharma4112.27 million88.87 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableMRVI, NAMS, GMTX, and RARE HeadlinesRecent News About These CompaniesUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Rating of "Moderate Buy" by AnalystsAugust 2 at 2:35 AM | americanbankingnews.comUltragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman SyndromeJuly 31 at 5:40 PM | manilatimes.netMUltragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick ResubmissionJuly 31 at 11:49 AM | finance.yahoo.comUltragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick ResubmissionJuly 31 at 11:49 AM | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 31 at 10:00 AM | prnewswire.comQ2 Earnings Estimate for RARE Issued By HC WainwrightJuly 31 at 6:34 AM | marketbeat.comUltragenyx Pharmaceutical (RARE) to Release Earnings on ThursdayJuly 31 at 4:18 AM | marketbeat.comWhat is HC Wainwright's Forecast for RARE Q2 Earnings?July 31 at 2:19 AM | americanbankingnews.comUltragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate UpdateJuly 30 at 8:30 AM | globenewswire.com43,274 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by GSA Capital Partners LLPJuly 30 at 4:42 AM | marketbeat.comSkandinaviska Enskilda Banken AB publ Invests $1.18 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)July 30 at 4:42 AM | marketbeat.comHC Wainwright Upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to BuyJuly 30 at 2:31 AM | americanbankingnews.comUltragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 CatalystJuly 29, 2025 | seekingalpha.com3RARE : Beyond The Numbers: 7 Analysts Discuss Ultragenyx Pharmaceutical StockJuly 28, 2025 | benzinga.comUltragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent SetbacksJuly 28, 2025 | benzinga.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 28, 2025 | globenewswire.comHC Wainwright Reaffirms "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)July 28, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from AnalystsJuly 28, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 27, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRVI, NAMS, GMTX, and RARE Company DescriptionsGemini Therapeutics NASDAQ:GMTX$58.97 -0.79 (-1.32%) As of 08/1/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Maravai LifeSciences NASDAQ:MRVI$2.22 -0.12 (-5.13%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 08/1/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.NewAmsterdam Pharma NASDAQ:NAMS$21.28 -0.53 (-2.43%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.28 0.00 (0.00%) As of 08/1/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Ultragenyx Pharmaceutical NASDAQ:RARE$28.44 +1.12 (+4.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$28.34 -0.11 (-0.37%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
